Find out about our latest press releases and publications and keep updated on our clinical studies

NOUS-PEV demonstrated good safety and immunogenicity, and induced durable neoantigen-specific T cell responses that were detected for over 6 months and increased T cell infiltration in tumors [...]

BASEL, Switzerland – 15th March 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, today announced that new [...]

We are glad to announce the following promotions of our team members: Loredana Siani to Vice President of Technical and CMC Development, Tiffany Brooke Muller to Senior Vice President of Finance [...]

We are thrilled to welcome Sarah Runswick as Senior Director of Clinical Science at Nouscom. Sarah is an experienced global clinical scientist with over 20 years expertise in early and late stage [...]

We are thrilled to welcome Yen-Ching Chua as VP of Clinical Operations at Nouscom. Yen-Ching is an experienced global clinical operations leader with over 20 years expertise in leading [...]

BASEL, Switzerland – 5th January 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered into [...]

Please find the full report below:

BASEL, Switzerland – 15th November 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced the first patient has [...]

Initial data from Phase 1b trial evaluating NOUS-PEV in combination with pembrolizumab to be presented at SITC 2022 BASEL, Switzerland – 7th November 2022 – Nouscom, a clinical stage [...]

D’Alise AM et al. Sci Transl Med 2022